Bioreactors

Cell therapy market to triple in size by 2025

04-Mar-2019 By Ben Hargreaves

The market for cell therapy products is set to expand based on increasing investment from the industry and the implementation of advanced manufacturing technologies.

Boehringer expands commercial biologics production capacity in China

22-Jan-2019 By Ben Hargreaves

Boehringer will increase its capacity for commercial manufacturing of biologics at its Shanghai, China, facility.

Fujifilm invests $112m on two fronts with new site and expansion

08-Jan-2019 By Ben Hargreaves

Fujifilm has launched an upgrade to its subsidiaries manufacturing capabilities, by increasing capacity by 50% at an existing facility and building an entirely new site for cell technology.

NEWS IN BRIEF

Biologics CDMO completes €5m expansion in Spain

18-Dec-2018 By Staff Reporter

Biologics and cell therapy CDMO, 3P Biopharmaceuticals, has expanded its facility and capabilities in Pamplona, Spain.

Q&A

UK cell and gene therapy ecosystem ‘second to none’

26-Nov-2018 By Ben Hargreaves

The UK has a ‘rich and vibrant’ advanced therapeutic manufacturing sector well placed to attract companies post-Brexit, says Keith Thompson, CEO of CGTC.

UK invests to streamline manufacture of next-gen medicine

23-Nov-2018 By Ben Hargreaves

Funding of £7.3m will be provided across three initiatives, with the long-term aim of providing patients with access to cell and gene therapies at a faster rate.

GE Healthcare strengthens single-use manufacturing in China

09-Nov-2018 By Ben Hargreaves

GE Healthcare will manufacture single-use consumables for bioprocessing through a collaboration with Wego.

NEWS IN BRIEF

WuXi Biologics breaks ground on $240m manufacturing site near Beijing

09-Nov-2018 By Flora Southey

Construction has started at WuXi Biologics’ eighth drug substance manufacturing facility, which CEO Chris Chen says will enable the CDMO to “develop and manufacture biologics more cost effectively”.

BIO Europe 2018

#BIOEurope: ‘Deal making is off the charts and the IPO window is open’

08-Nov-2018 By Flora Southey

Denmark played host to its first BIO Europe this week, welcoming 4,500 attendees from across the globe – including growing numbers from China and South Korea.

Astellas invests $256m in cell therapy manufacturing buildout

07-Nov-2018 By Ben Hargreaves

The company will construct two facilities in Japan and relocate its regenerative medicine facility in the US.

CAR-T manufacture ‘where mAbs were in the early 1990s’, says bluebird CTMO

05-Nov-2018 By Ben Hargreaves

With cell and gene therapies developing at a rapid pace, it leaves significant questions as to how manufacturing processes are keeping up.

Avid expansion to triple process development capacity, says CEO

25-Oct-2018 By Ben Hargreaves

Avid continues its transition to a fully-fledged CDMO by transforming its process development capabilities with new lab space.

BIA Bioscience Forum

Four major barriers to efficient cell & gene manufacture

22-Oct-2018 By Ben Hargreaves

BIA’s Bioscience Forum brought together four experts on cell and gene manufacture to discuss what difficulties are being faced in the industry and how they are reacting to them.

Report: Bioprocessing trends 2018-2023

08-Oct-2018 By Flora Southey

Increased cell and gene therapy production and reduced development timelines are listed among bioprocessing trends predicted over the next five years, says consultant.

NEWS IN BRIEF

BIA Separations adds upstream processing facility

28-Sep-2018 By Ben Hargreaves

BIA Separations has completed work on an additional upstream processing laboratory in Ajdovščina, Slovenia.

Pall collaborates with Aetos for ‘next-gen’ biosimilar manufacturing

26-Sep-2018 By Maggie Lynch

Pall has entered an agreement with Aetos Biologics to provide manufacturing solutions for expedited biosimilar development.

BeiGene adopts GE ‘turnkey’ factory for anti-PD-1 mAb production

25-Sep-2018 By Flora Southey

BeiGene will use GE Healthcare Life Sciences’ ‘off-the-shelf’ factory to manufacture monoclonal antibodies in Guangdong Province, China.

Lonza invests $418m in two biomanufacturing solutions

21-Sep-2018 By Ben Hargreaves

Lonza announced it would invest in two new “Ibex Solutions”, which offer manufacturing capabilities to biotechs developing antibody therapies.

Thermo Fisher expands bioprocessing with BD acquisition

14-Sep-2018 By Ben Hargreaves

Thermo Fisher Scientific announced the acquisition of BD’s Advanced Bioprocessing unit, which will join its Life Sciences Solution business.

Q&A

Plant-derived rituximab? iBio inks ‘green’ bioreactor tech deal in China

10-Sep-2018 By Flora Southey

iBio has partnered with CC-Pharming to develop and manufacture a monoclonal antibody using whole plants.

ABEC to supply China’s ‘rapidly growing’ biopharma industry from Ireland

28-Aug-2018 By Flora Southey

China has accredited ABEC to make and supply bioprocessing equipment from its Kells facility in Ireland.

Algenuity develops green solution for pharma with algae platform

07-Aug-2018 By Ben Hargreaves

Algenuity has launched the MERIT project to develop renewable methods of producing therapeutic agents.

UK invests in cell and gene therapy workforce to prepare for commercial products

29-May-2018 By Nick Taylor

The UK is investing £3m ($4m) to build a workforce capable of delivering cell and gene therapies to patients at commercial scales.

WuXi Biologics says Ireland an attractive option post-Brexit, invests €325m

02-May-2018 By Flora Southey

The Chinese CDMO says it will build a biomanufacturing facility in Ireland with single-use bioreactors and continuous bioprocessing capabilities.

GE launches modular bioprocessing facility for viral vector vaccines

17-Apr-2018 By Flora Southey

GE Healthcare Life Sciences has launched a prefabricated, modular bioprocessing facility designed for the manufacture of viral vector-based therapeutics.

Bio-Separation: Our outgoing editor looks back over 5 years

13-Apr-2018 By Dan Stanton

Biopharma-Reporter editor Dan Stanton is finally packing his buffer bag and moving upstream.

UPDATE

Amgen picks Rhode Island location for next-gen biomanufacturing

11-Apr-2018 By Flora Southey

Rhode Island will be the home of Amgen’s first US next-generation biomanufacturing plant, based on the firm’s modular, single-use site in Singapore.

MilliporeSigma: Filling gaps in continuous bioprocessing will lower COGS

10-Apr-2018 By Dan Stanton

Vendors can help address technology gaps but industry must look to collaborations and internal development to create fully continuous bioprocesses, says MilliporeSigma.

Takeda’s off-the-shelf stem cell therapy approved in Europe

27-Mar-2018 By Dan Stanton

Alofisel (darvadstrocel) has become the first allogeneic stem cell product to be approved in Europe.

WuXi Biologics adds 4,000L bioreactors at fully single-use site

21-Mar-2018 By Dan Stanton

The CMO says adding the single-use offering from ABEC will make the newly opened biomanufacturing site in China comparable to stainless steel for commercial mAb production.

News in brief

ABL Europe equips viral vector plant with Sartorius single-use tech

16-Mar-2018 By Staff Reporter

Both upstream and downstream systems provided by Sartorius Stedim Biotech have been installed in ABL’s facility in Strasbourg, France.

Up to down: BIA and Nuvonis to address ‘last frontier in bioprocessing’

15-Mar-2018 By Dan Stanton

BIA Separations has teamed with Nuvonis Technologies to help vaccine and cell therapy developers tackle the transition from upstream to downstream processing.

NEWS IN BRIEF

WuXi BioLogics wins Adagene antibody therapeutics contract

13-Mar-2018 By Flora Southey

WuXi BioLogics will develop and manufacture Adagene’s antibody therapeutics for the Chinese market before expanding globally.

AGC Biologics adds 2,000L single-use bioreactor in CA

09-Mar-2018 By Dan Stanton

The biologics CDMO will install a 2,000L single-use bioreactor (SUB) from Thermo Fisher Scientific at its Berkeley facility to meet demand for early-phase projects.

Beyond mammalian culture: ABEC’s single-use range to cover microbial fermentation

07-Mar-2018 By Flora Southey

Bioprocessing vendor ABEC has added microbial fermentation capabilities to its single-use line.

Made in Ireland: ABEC adds cleanroom to make large-scale disposable tech

27-Feb-2018 By Flora Southey

ABEC has expanded manufacturing in Ireland with the completion of an ISO-7 cleanroom, where the single-use vendor will make disposable bioreactor bags for global distribution.

Samsung BioLogics wins potential $148m contract at new plant

23-Feb-2018 By Dan Stanton

The manufacturing contract is the first of what Samsung BioLogics expects to be a number of long-term partnerships at its recently completed 180,000L facility.

Perfusion to fed-batch: Repligen record quarter for ATF tech

23-Feb-2018 By Dan Stanton

Repligen says the single-use version of its alternating tangential flow (ATF) platform is helping the firm capture a larger share of the fed-batch bioreactor marketplace.

Dyadic enters R&D deal for its fungus-based expression system

21-Feb-2018 By Dan Stanton

“There is a new kid on the block to rival E. Coli, CHO and yeast,” says Dyadic International as it collaborates to widen the use of its C1 expression tech.

Q&A

AbSci hopes to make E. Coli great again through engineered expression system

07-Feb-2018 By Dan Stanton

AbSci says its genetically engineered E. coli expression platform has produced yields exceeding 20 g/L for difficult to express products and threatens the dominance of mammalian systems.

Bigger in Texas: Fujifilm adds 6,000L and opens gene therapy plant

30-Jan-2018 By Dan Stanton

The need for CDMOs with commercial gene therapy capacity is growing says Fujilfilm Diosynth Biotechnologies, which has opened an 80,000 square-foot plant in Texas.

GE wins another FlexFactory fit out in ‘big market’ China

24-Jan-2018 By Flora Southey

Clover Biopharmaceuticals will adopt GE Healthcare’s centrally automated FlexFactory platform at its facility in Zhejiang, China where it plans to make a biosimilar to Amgen’s Enbrel.

Paragon expansion to address ‘deficit in gene therapy CDMO capacity’

24-Jan-2018 By Dan Stanton

The CDMO says it is building a 150,000 square-foot biomanufacturing facility in Maryland in preparation for a double-digit growth in the gene therapy space.

Sanofi to pay $11.6bn for Bioverativ for haemophilia biz and commercial network

23-Jan-2018 By Gareth Macdonald

Sanofi has agreed to buy Bioverativ Inc. for $11.6bn for haemophilia business and to help develop its candidate RNAi therapeutic fitusiran.

Cellular Biomedicine Group adopts GE Healthcare tech for CAR-T therapy production

19-Jan-2018 By Gareth Macdonald

Cellular Biomedicine Group Inc (CBMG) has selected GE Healthcare’s FlexFactory technology for its CAR-T therapy production facility in Shanghai, China.

Celltrion looks overseas and scraps 120,000L Korean facility plans

17-Jan-2018 By Dan Stanton

Celltrion has shelved plans for a third biomanufacturing plant at its site in Incheon in favour of an overseas site it says will help ensure biosimilar supply.

Product characterisation key to successful CAR T therapies, Autolus

16-Jan-2018 By Dan Stanton

CAR T-cell understanding must come before the process design if such therapies are ever going to be accessible to a larger patient population, says Autolus.

CombiGene asks UK CGT Catapult to help make epilepsy gene therapy for trials

12-Jan-2018 By Gareth Macdonald

CombiGene AB has asked the Cell and Gene Therapy Catapult to develop manufacturing processes for its candidate epilepsy gene therapy, CG01.

VC banks on CAR T through acoustic wave separation firm investment

12-Jan-2018 By Dan Stanton

Venture capital company Dynamk Capital has invested in FloDesign Sonics citing its acoustic wave separation technology’s application in the growing CAR T cell sector.

Abzena selects Sartorius single-use bioreactors for US sites

05-Jan-2018 By Flora Southey

Sartorius Stedim Biotech will supply disposable bioreactors at Abzena’s CDMO facilities in the US.